FDA Considers Approval of CRISPR-Based Treatment to Combat Sickle Cell Disease
4 months ago
The FDA's independent advisory committee is evaluating a gene therapy treatment called exa-cel that uses CRISPR gene editing to potentially cure sickle cell disease. Sickle cell disease is a genetic blood disorder with no cure where red blood cells become misshapen and can cause organ damage, severe pain episodes, and early death. Exa-cel therapy alters a patient's own stem cells using CRISPR to fix the genetic mutation that causes sickle cell disease. The FDA will make a final approval decision on exa-cel therapy by December 8th after considering the committee's perspectives.
New Study Suggests CRISPR Gene Editing Might Alter DNA & Turn Cells Cancerous
FDA gives preliminary approval for trial to deploy genetically engineered mosquitoes to fight Zika
Gene-editing treatment shows promise for sickle cell disease, and other top stories in US news from December 06, 2020.
McDonald's Burgers में Fake Cheese? Ban करने की उठी मांग| McDonald's ने लोगों को ठगा? GoodReturns
Kim Jong Un Unveils Ambitious 'Regional Development Policy' To Modernize Rural North Korea Amid Food Shortages
'Nothing Is Secure': Tucker Carlson Accuses NSA Of Intercepting And Leaking Encrypted Signal Chats
Les phages coopèrent pour désactiver les défenses CRISPR des bactéries qu'ils attaquent
Fresh Express Recalls More Than 200 Fresh Salad Products Due to Potential Listeria Contamination